CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference
CytoSorbents Corporation (NASDAQ: CTSO) has announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. CEO Dr. Phillip Chan will engage in a fireside chat with Danielle Antalffy, highlighting the company's progress and future outlook. CytoSorbents specializes in critical care immunotherapy and its flagship product, CytoSorb®, is widely used for blood purification in critically ill patients. The technology is approved in the EU and has been utilized in over 121,000 treatments globally.
- None.
- None.
MONMOUTH JUNCTION, N.J., Feb. 16, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation in the 10th Annual SVB Leerink Global Healthcare Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will discuss the Company's progress and outlook with Danielle Antalffy, Managing Director, Medical Devices, Equity Research at SVB Leerink in a fireside chat format. Company management will also meet with investors in 1x1 meetings that are currently being scheduled, throughout the day. If interested, please contact your SVB Leerink representative.
SVB Leerink Annual Global Healthcare Conference
When: Wednesday, February 24, 2021 from 4:20PM-4:50PM EST
Webcast: SVB Leerink Presentation Webcast Link
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 67 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used in more than 121,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma), and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions, including statements regarding our expectations about our cash runway, the advancement of our trials, our plans to initiate new trials, our goals to develop and commercialize CytoSorb and the timing thereof, the potential impact of COVID-19 on our operations and milestones, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Cytosorbents Contact:
Amy Vogel
Investor Relations
732-398-5394
avogel@cytosorbents.com
Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3055
ekim@rubensteinpr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-301228704.html
SOURCE CytoSorbents Corporation
FAQ
What is CytoSorbents Corporation's stock symbol?
When is CytoSorbents participating in the SVB Leerink Global Healthcare Conference?
Who will represent CytoSorbents at the conference?
What is the significance of CytoSorb® for critically ill patients?
How many countries is CytoSorb® approved for use in?
